What is the half-life of ARA-290 (Cibinetide)?
ARA-290 (Cibinetide) has a reported half life of ~20 min terminal (subcutaneous; ~2 min IV), given subcutaneous. That is why it is typically dosed once daily. A shorter half life means more frequent dosing to keep blood levels steady, a longer one lets you space doses further apart.
Quick facts
- Half-life: ~20 min terminal (subcutaneous; ~2 min IV)
- Route: Subcutaneous
- Typical schedule: Once daily
- Cycle length: 4-12 weeks
References
- ARA-290 (cibinetide) in sarcoidosis-associated small fiber neuropathy — Heij L et al., Mol Med, 2012
- ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density — Dahan A, Dunne A, Swartjes M, et al. (Brines M, senior author) — Molecular Medicine, 2013
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes — Brines M, Dunne AN, van Velzen M, et al. — Molecular Medicine, 2015
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on ARA-290 (Cibinetide)
Last updated 2026-06-06.